Technical Analysis for TAK - Takeda Pharmaceutical Company Limited

Grade Last Price % Change Price Change
D 16.94 0.59% 0.10
TAK closed up 0.59 percent on Thursday, May 13, 2021, on approximately normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical TAK trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Inside Day Range Contraction 0.00%
20 DMA Resistance Bearish 0.59%
Bollinger Band Squeeze Range Contraction 0.59%
Fell Below 20 DMA Bearish 1.38%
Hammer Candlestick Bullish 1.38%
Bollinger Band Squeeze Range Contraction 1.38%
BB Squeeze + Lower Band Touch Range Contraction 1.38%
Gapped Down Weakness 1.38%
Older End-of-Day Signals for TAK ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 7 hours ago
Possible Inside Day about 7 hours ago
20 DMA Resistance about 11 hours ago
Rose Above 20 DMA about 11 hours ago
20 DMA Resistance 1 day ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Takeda Pharmaceutical Company Limited Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers medicines in various therapeutic areas, including gastroenterology; cancer; neurological and psychiatric diseases; and rare diseases, such as immunology and hematology, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Pharmaceutical Industry Immunology Pharmaceutical Products Pharmacy Rare Diseases Hematology Healthcare Products Healthcare Product Specialty Drugs Gastroenterology Takeda Pharmaceutical Company Cancer Center University Of Texas Nasdaq Biotechnology Index Arcturus Therapeutics Novimmune

Is TAK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 20.0
52 Week Low 15.3
Average Volume 2,590,094
200-Day Moving Average 17.82
50-Day Moving Average 17.74
20-Day Moving Average 16.85
10-Day Moving Average 16.77
Average True Range 0.28
ADX 25.69
+DI 21.66
-DI 34.54
Chandelier Exit (Long, 3 ATRs ) 16.43
Chandelier Exit (Short, 3 ATRs ) 17.21
Upper Bollinger Band 17.14
Lower Bollinger Band 16.55
Percent B (%b) 0.66
BandWidth 3.50
MACD Line -0.22
MACD Signal Line -0.28
MACD Histogram 0.0664
Fundamentals Value
Market Cap 52.97 Billion
Num Shares 3.13 Billion
EPS 0.81
Price-to-Earnings (P/E) Ratio 20.87
Price-to-Sales 1.87
Price-to-Book 1.29
PEG Ratio 0.12
Dividend 0.84
Dividend Yield 4.96%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.24
Resistance 3 (R3) 17.22 17.10 17.19
Resistance 2 (R2) 17.10 17.02 17.11 17.17
Resistance 1 (R1) 17.02 16.98 17.06 17.04 17.16
Pivot Point 16.90 16.90 16.92 16.91 16.90
Support 1 (S1) 16.82 16.82 16.86 16.84 16.72
Support 2 (S2) 16.70 16.78 16.71 16.71
Support 3 (S3) 16.62 16.70 16.69
Support 4 (S4) 16.64